尽管近年来在诊断和治疗方面取得了大规模的进展，但成年原发恶性脑肿瘤的异质性和治疗管理对医生造成了重大挑战。根据过去20年来的研究和经验积累，已经概述了可以从复杂肿瘤学治疗中获益最多的患者范围，并且已经确认可靠的复杂诊断背景是充分治疗管理的必要条件。然而，在一些必要的治疗步骤之后，“黄金标准”的磁共振成像（MRI）并不总能准确评估和诊断治疗后的情况。得益于核医学和神经肿瘤学职业的合作，越来越多的放射性示踪剂化合物现在已经在越来越多的中心可用，包括氨基酸配体，因此，具有放射性药物O-(2-[18F]氟乙基)-L-酪氨酸的正电子发射断层显像（PET）检查。代谢状态作为一种第四维成像是充分现代诊断的重要组成部分。将先进的MRI技术与基于PET的（PET/CT、PET/MRI）测量结合使用适当的示踪剂可以使治疗决策建立在可靠的基础上。我们通过回顾匈牙利和国外方法实践的文献数据，并展示我们迄今为止的回顾性总结研究的结果，展示了氨基酸-PET基于混合核医学成像研究在这些患者的治疗管理中的临床意义。《Orv Hetil》2023年；164（32）：1247-1255。

Despite the large-scale diagnostic and therapeutic progress of recent years, the heterogeneity and therapeutic management of adult primary malignant brain tumors pose a significant challenge to the attending physician. Based on the research and experience accumulated over the past two decades, the range of patients who can benefit the most from complex oncology treatment has been outlined, and it has been confirmed that a reliable complex diagnostic background is essential for adequate therapeutic management. However, after some necessary therapeutic steps, the "gold standard" magnetic resonance imaging (MRI) is not always able to accurately assess and diagnose post-therapeutic conditions. Thanks to the collaboration of the nuclear medicine and neuro-oncology professions, more and more types of radiotracer compounds are now available in more and more centers, including amino acid ligands and thus, positron emission tomography (PET) examinations with the radiopharmaceutical O-(2-[18F]fluoroethyl)-L-tyrosine. The metabolic state, as a kind of fourth dimension of imaging, is an essential part of adequate modern diagnostics. Combining advanced MRI techniques and PET-based (PET/CT, PET/MRI) measurements with a suitable tracer can place therapeutic decisions on a reliable basis. We present the clinical significance of amino acid-PET-based hybrid nuclear medicine imaging studies in the therapeutic management of these patients by reviewing the literature data on the practice of the method in Hungary and abroad and presenting the results of our retrospective summary research so far. Orv Hetil. 2023; 164(32): 1247-1255.